← Leaderboards
Daniel Lyndon Jaffe Thorek
Johns Hopkins University
$4,988,087
Attributed
$6,495,335
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,495,335 · 5
By mechanism
R01$6,110,472 · 4
R21$384,863 · 1
Top collaborators
- Jeff M Michalski5 shared
- Abhinav K Jha1 shared
- Yuan-Chuan Tai1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Yong Du$6,226,551
- Dara L Kraitchman$14,405,090
- Martin G Pomper$38,517,075
- Robert Francois Hobbs$5,138,973
- Hao Wang$2,348,301
Others in their field
Other Emerging Leaders on “Tissues”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$61,115,130
- Leonard Freedman · Leidos Biomedical Research, Inc.$54,559,980
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Evan Z Macosko · Broad Institute, Inc.$33,867,067
Research focus
TissuesSiteImageMonitorDrug KineticsParticle TherapyRadiation TherapyDoseOrganCellsDiscipline Of Nuclear MedicineUptakePathologyMetastatic Neoplasm To The BoneCessation Of LifeMolecularMalignant NeoplasmsMalignant Neoplasm Of ProstateRadiology SpecialtyBiologicalProstate Cancer ModelCancer EtiologyFallsAlpha Particles
Grant awards (18)
Sensing Collimator Technology for Ultrasensitive SPECT Imaging of Targeted Radiopharmaceutical Therapies$598,134
R01 · FY2025 · EB
The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities$414,138
R01 · FY2024 · CA · contact PI
Antibiotic-based PET Imaging of Implant Associated Gram-positive Bacterial Infections$384,863
R21 · FY2024 · EB · contact PI
Opening the Therapeutic Window for PSMA-Targeted Molecular Radiotherapy$163,774
R01 · FY2024 · CA · contact PI
The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities$429,037
R01 · FY2023 · CA · contact PI
Opening the Therapeutic Window for PSMA-Targeted Molecular Radiotherapy$186,509
R01 · FY2023 · CA · contact PI
The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities$425,321
R01 · FY2022 · CA · contact PI
Opening the Therapeutic Window for PSMA-Targeted Molecular Radiotherapy$366,376
R01 · FY2022 · CA · contact PI
The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities$432,694
R01 · FY2021 · CA · contact PI
Opening the Therapeutic Window for PSMA-Targeted Molecular Radiotherapy$377,875
R01 · FY2021 · CA · contact PI
The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities$515,794
R01 · FY2020 · CA · contact PI
Opening the Therapeutic Window for PSMA-Targeted Molecular Radiotherapy$401,180
R01 · FY2020 · CA · contact PI
Kallikrein-Targeted Alpha-Particle Therapy of Late-Stage Prostate Cancer$322,244
R01 · FY2020 · CA · contact PI
Opening the Therapeutic Window for PSMA-Targeted Molecular Radiotherapy$403,303
R01 · FY2019 · CA · contact PI
Kallikrein-Targeted Alpha-Particle Therapy of Late-Stage Prostate Cancer$326,508
R01 · FY2019 · CA · contact PI
Kallikrein-Targeted Alpha-Particle Therapy of Late-Stage Prostate Cancer$193,383
R01 · FY2018 · CA · contact PI
Kallikrein-Targeted Alpha-Particle Therapy of Late-Stage Prostate Cancer$180,862
R01 · FY2018 · CA · contact PI
Kallikrein-Targeted Alpha-Particle Therapy of Late-Stage Prostate Cancer$373,340
R01 · FY2017 · CA · contact PI